In Brief: Guidant
This article was originally published in The Gray Sheet
Executive Summary
Guidant: Firm's CPI subsidiary gains FDA approval via premarket approval application supplement for its Ventak PRx III automatic implantable cardioverter defibrillator system. The system, used in the treatment of tachycardia includes the PRx III biphasic pulse generator, the Endotak lead, and a program monitor. The PRx III pulse generator, 30% smaller than Guidant's currently marketed PRx and P2 devices, has been marketed in Europe since October 1994. According to Guidant, labeling for PRx III does not specify implantation location, but the firm notes that more that 50% of European patients have been implanted pectorally. The PRx III pulse generator lists for $19,900; the entire system will sell for $26,400...
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.